The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

Not Applicable

Not yet recruiting

• Conditions: Metabolic Dysfunction Associated Fatty Liver Disease; Compensated Liver Cirrhosis
• Interventions: Drug: Chiglitazar 64mg; Drug: Placebo

• Registration Number: NCT06773221
• Lead Sponsor: Beijing Friendship Hospital

Brief Summary

A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms. One arm will receive Chiglitazar(64 mg) treatment, while the other arm will receive placebo treatment, lasting for 72 weeks. Both the researchers and the participants will be blinded. The primary outcome is the reversal rate of cirrhosis assessed by magnetic resonance elastography. Secondary outcomes include outcome events, changes in histopathological fibrosis stage, non-invasive fibrosis tests, glucose and lipid metabolism indicators.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-01
• Study First Submitted: 2025-01-02
• Study First Submitted QC: 2025-01-08
• Last Update Submitted: 2025-01-13
• Study First Posted: 2025-01-14
• Last Update Posted: 2025-01-15
• Study Start: 2025-02-05
• Primary Completion: 2028-01-31
• Study Completion: 2028-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

1. Men and women aged between 18 and 75 years (inclusive) who understand and sign informed consent forms; 2. Compensated MAFLD-related cirrhosis diagnosis(meet one of the following conditions):

2. The liver biopsy during the screening period (liver biopsy within 6 months of screening is acceptable) showing cirrhosis with steatohepatitis according to the Non Alcoholic Fatty Liver Disease Clinical Research Network (NASH-CRN) scoring system, and there is no evidence of competitive aetiology.

3. The liver biopsy during the screening period (liver biopsy within 6 months of screening is acceptable) showing cirrhosis with steatosis (no steatohepatitis) according to NASH-CRN scoring system, and there is no evidence of competitive aetiology. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and/or type 2 diabetes mellitus (T2DM).

4. Historical biopsy showed steatohepatitis, and now diagnosed with cirrhosis through non-invasive tests or clinical criteria (see criterion (5)-1)). There is no evidence of competing aetiology. There is at least 1 coexisting or history of metabolic comorbidity.

5. Historical biopsy showed steatosis (no steatohepatitis), and now diagnosed with cirrhosis through non-invasive tests or clinical criteria (see criterion (5)-1)). There is no evidence of competing aetiology. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and/or T2DM.

6. In the absence of biopsy, MAFLD-related cirrhosis is defined based on the following criterias:

   a. Cirrhosis is defined based on one of the following non-invasive tests(NITS): i: MRE ≥ 5kPa or VCTE-LSM ≥ 20kPa (when the patients with BMI ≥ 28kg/m2 , MRE ≥ 5kPa must also be met); ii:VCTE ≥15 kPa and <20 kPa and 1 of the following: MRE≥4.45kPa or Agile4≥0.565 or Platelets≤150,000/µL; iii: VCTE <15 kPa and 2 of the following: MRE≥4.45kPa or Agile4≥0.565 or Platelets≤150,000/µL; b. Current or previous imaging examinations have diagnosed fatty liver or controlled attenuation parameter (CAP)>288dB/m or magnetic resonance imaging proton density fat fraction (MRI-PDFF)>5%.

   c. There is no evidence of competing aetiology; d. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and/or T2DM.

7. If a participant's MAFLD-related cirrhosis diagnosis for eligibility is based on the biopsy screening period , no weight loss of ≥10% should have occurred in the same time period (based on medical history).

Exclusion Criteria

1. Other chronic liver diseases (including but not limited to viral hepatitis, alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, Wilson's disease, hemochromatosis, etc.)

2. There has been a continuous history of heavy drinking for 3 months or more current or rencent 5 years (heavy drinking is defined as >20 g/day in women and >30 g/day in men); Or researchers can not reliably quantify alcohol consumption.

3. Hepatic decompensation events (including ascites, esophageal and gastric variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, etc.) or hepatocellular carcinomaor.

4. History of malignant tumors within 5 years (excluding local squamous cell carcinoma of the skin or treated cervical intraepithelial neoplasia)；

5. Combination of autoimmune diseases (including but not limited to systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, etc.)；

6. Combined with severe esophageal and gastric varices and/or positive red sign accessed by endoscope；

7. History of liver transplantation or bone marrow transplantationor or listed for liver transplantation;

8. Previous (<5 years before screening)or planned (during the trial period) treatment for obesity with surgery;

9. Have obesity induced by other endocrinologic disorders (i.e. Cushing Syndrome) genetic diseases;

10. Secondary factors that can cause liver steatosis, such as malnutrition, medication, genetic metabolic diseases, etc.

11. Individuals with the following abnormal indicators:

    1. Alanine aminotransferase (ALT)>5 * ULN;
    2. Aspartate aminotransferase (AST)>5 * ULN
    3. Direct bilirubin (DBIL)>1.5 * ULN
    4. Estimated glomerular filtration rate (eGFR)<60 mL/min/1.73m2
    5. Glycated hemoglobin (HbA1c)>10%
    6. MELD score ≥ 12 or Child Pugh score ≥ 8 caused by liver disease

12. History of any type of diabetes than T2DM;

13. Participants receive more than 1 month of treatment with any of the following drugs within 6 months before screening: thiazolidinedione (TZD), glucagon like peptide-1 (GLP-1) receptor agonists, bate lipid-lowing drugs, liver selective thyroxine receptor beta (TSH - β) agonists, obeticolic acid, insulin, berberine, weight-loss drugs, amiodarone, methotrexate, systemic glucocorticoids at >5 mg/day of prednisone equivalent, tamoxifen, oestrogens at doses higher than those used for hormone replacement or contraception, anabolic steroids except testosterone replacement, valproic acid, and known hepatotoxins;

14. Participants receive the following medications unless they have received a stable dose of at least 1 month prior to screening: beta blockers, thiazide diuretics, statins, niacin, ezetimibe, thyroid hormones, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter (SGLT-2) inhibitors, sulfonylureas, gliptides, alpha glucosidase inhibitors;

15. Participating in clinical trials of other drugs or medical devices within the past 3 months.

16. Participants who demonstrate recent evidence (within 6 months prior to screening) of acute or unstable cardiovascular and cerebrovascular events events (such as hospitalisation for myocardial infarction, stroke, chronic heart failure grade IV (NYHA classification), severe arrhythmia, left ventricular hypertrophy, transient ischemic attack, and/or acute peripheral vascular events);

17. QTc (Fridericia) mean interval that is greater than 500 ms at screening (triplicate electrocardiogram [ECG]) or personal or family history of long QT syndrome;

18. Have a history of major surgery or fracture in the past 3 months;

19. Severe osteoporosis or other known bone diseases, or other conditions that may lead to fractures accessed by researchers;

20. History of lower limb or systemic edema;

21. Contraindications for MRI scans, including but not limited to: cerebral aneurysm clips, implanted nerve stimulators, implanted pacemakers or defibrillators, or the presence of artificial heart valves, cochlear implants, potentially ferromagnetic intraocular foreign bodies (such as metal shavings), other implantable medical devices (such as insulin pumps), metal shrapnel or bullets remaining in the body, severe claustrophobia, tattoos (determined by the researcher and radiologist), weight exceeding the carrying capacity of the MRI scanner, etc.;

22. Positive for human immunodeficiency virus (HIV) infection;

23. History of drug use or abuse of drugs within the 12 months prior to screening.

24. patients who have smoked heavily within the past year, with a daily intake of ≥ 30 cigarettes;

25. Pregnant or lactating women, and the woman of childbearing age who are unable or unwilling to use adequate contraception;

26. Researchers believe that patients who are not suitable to participate in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment arm	Chiglitazar 64mg	Chiglitazar 64mg, oral, qd, for 72 weeks
Control arm	Placebo	Placebo, oral, qd, for 72 weeks

Primary Outcome Measures

Name	Time	Method
Fibrosis regression rate	72 weeks	20% decline in magnetic resonance elastography(MRE)

Secondary Outcome Measures

Name	Time	Method
Cumulative incidence of outcomes events	72 weeks	Cumulative incidence of outcomes events(including liver decompensation, hepatocellular carcinoma, liver transplantation, and death)
Percentage of participants acheving decline in fibrosis stage in histopathology	72 weeks	changes in fibrosis stage in histopathology
Number of patients with decreased scores of non-invasive liver fibrosis tests	weeks 2, 4, 8, 12, 18, 24, 32, 40, 48, and 72.	Dynamic change of non-invasive liver fibrosis tests(including APRI、FIB-4、FAST、NFS)
Number of patients with decrease of MRE	weeks 48, and 72.	absolute change of MRE, and percentage of patients achieving 15% decline in MRE
Number of patients with change in magnetic resonance imaging-derived proton density fat fraction(MRI-PDFF))	weeks 48, and 72.	absolute change in MRI-PDFF, and percentage of patients achieving 30% decline in MRI-PDFF
Number of patients with decrease of liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE)	weeks12, 24, 48, and 72.	Absolute change in LSM, CAP, and SSM, and percentage of patients achieving 30% decline in LSM
Number of patients with change in spleen stiffness measurement (SSM)) via vibration-controlled transient elastography (VCTE)	weeks12, 24, 48, and 72.
Number of patients with change in controlled attenuation parameter(CAP) via vibration-controlled transient elastography (VCTE)	weeks12, 24, 48, and 72.
Number of patients with decrease in glycosylated hemoglobin A1c (HbA1c)	weeks12, 24, 48, and 72.
Number of patients with change in lipidmetabolism indicators.	weeks 2, 4, 8, 12, 18, 24, 32, 40, 48, and 72.	Dynamic changes in lipidmetabolism indicators (including triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and apolipoprotein B (Apo B))
Number of patients with change of liver function indictors	weeks 2, 4, 8, 12, 18, 24, 32, 40, 48, and 72.	Dynamic change of liver function indicators (including ALT and AST)
Number of patients with change in fast plasma glucose	weeks 2, 4, 8, 12, 18, 24, 32, 40, 48, and 72.

Trial Locations

Locations (4)

Beijing Ditan Hospital, Capital Medical University; 🇨🇳 Beijing, China

Peking University People's Hospital; 🇨🇳 Beijing, China

Beijing Friendship Hospital, Capital Medical University; 🇨🇳 Beijing, China

Beijing Youan Hospital, Capital Medical University; 🇨🇳 Beijing, China